Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Conditions:   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Gastric Cancer
Interventions:   Drug: TAS 102;   Drug: Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]
Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 13, 2019 / by / in
Comments